Intellia Therapeutics (NTLA) PT Lowered to $54 at RBC Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Intellia Therapeutics (NTLA) PT Lowered to $54 at RBC Capital

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

August 8, 2024 7:30 AM EDT

Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarterSelected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyOn track to initiate the Phase 3 study of... More